Latest Insider Transactions at Eye Point Pharmaceuticals, Inc. (EYPT)
This section provides a real-time view of insider transactions for Eye Point Pharmaceuticals, Inc. (EYPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EyePoint Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EyePoint Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,251
-12.57%
|
$281,275
$25.02 P/Share
|
|
Jan 24
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,251
+11.16%
|
$146,263
$13.02 P/Share
|
|
Jan 23
2024
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
5,044
-2.96%
|
$121,056
$24.97 P/Share
|
|
Jan 23
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,135
-6.36%
|
$128,375
$25.0 P/Share
|
|
Jan 23
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,135
+5.96%
|
$66,755
$13.02 P/Share
|
|
Jan 23
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
900
-1.16%
|
$22,500
$25.0 P/Share
|
|
Jan 23
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+1.15%
|
$7,200
$8.08 P/Share
|
|
Jan 22
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
34,166
-25.3%
|
$751,652
$22.47 P/Share
|
|
Jan 22
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,166
+18.55%
|
$341,660
$10.8 P/Share
|
|
Jan 11
2024
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
1,910,500
-95.02%
|
$36,299,500
$19.45 P/Share
|
|
Jan 11
2024
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
1,910,500
-95.02%
|
$36,299,500
$19.45 P/Share
|
|
Jan 11
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
750,000
+9.81%
|
$14,250,000
$19.75 P/Share
|
|
Jan 09
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
105,000
+1.68%
|
$2,205,000
$21.32 P/Share
|
|
Jan 08
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,913
-38.56%
|
$481,173
$21.13 P/Share
|
|
Jan 08
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,913
+27.83%
|
$68,739
$3.26 P/Share
|
|
Jan 06
2024
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,487
-10.95%
|
$89,740
$20.4 P/Share
|
|
Jan 06
2024
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+27.16%
|
-
|
|
Jan 06
2024
|
Nancy Lurker |
SELL
Payment of exercise price or tax liability
|
Direct |
23,043
-11.91%
|
$460,860
$20.4 P/Share
|
|
Jan 06
2024
|
Nancy Lurker |
BUY
Exercise of conversion of derivative security
|
Direct |
75,133
+27.97%
|
-
|
|
Jan 06
2024
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,966
-30.4%
|
$119,320
$20.4 P/Share
|
|
Jan 06
2024
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+43.78%
|
-
|
|
Jan 06
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,528
-13.05%
|
$130,560
$20.4 P/Share
|
|
Jan 06
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,793
+29.37%
|
-
|
|
Jan 06
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,147
-9.85%
|
$82,940
$20.4 P/Share
|
|
Jan 06
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+26.63%
|
-
|
|
Jan 06
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,911
-12.21%
|
$98,220
$20.4 P/Share
|
|
Jan 06
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+27.54%
|
-
|
|
Dec 13
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,458
-5.37%
|
$29,160
$20.0 P/Share
|
|
Dec 13
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,458
+5.09%
|
$14,580
$10.13 P/Share
|
|
Dec 08
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
588,235
+8.88%
|
$9,999,995
$17.0 P/Share
|
|
Dec 06
2023
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
266,242
-11.69%
|
$4,792,356
$18.41 P/Share
|
|
Dec 06
2023
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
266,242
-11.69%
|
$4,792,356
$18.41 P/Share
|
|
Dec 05
2023
|
Therapeutics Ocumension Director |
SELL
Open market or private sale
|
Direct |
733,758
-24.37%
|
$13,941,402
$19.91 P/Share
|
|
Dec 05
2023
|
Ye Liu |
SELL
Open market or private sale
|
Indirect |
733,758
-24.37%
|
$13,941,402
$19.91 P/Share
|
|
Dec 04
2023
|
Dario A. Paggiarino Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,625
-54.37%
|
$673,750
$22.0 P/Share
|
|
Dec 04
2023
|
Dario A. Paggiarino Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,625
+35.22%
|
$306,250
$10.13 P/Share
|
|
Dec 04
2023
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
SELL
Open market or private sale
|
Direct |
45,000
-89.39%
|
$990,000
$22.0 P/Share
|
|
Dec 04
2023
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+47.2%
|
$540,000
$12.62 P/Share
|
|
Dec 04
2023
|
Nancy Lurker |
SELL
Open market or private sale
|
Direct |
20,000
-10.5%
|
$400,000
$20.76 P/Share
|
|
Dec 04
2023
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
1,919,057
+2.16%
|
$49,895,482
$26.82 P/Share
|
|
Sep 01
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-0.57%
|
$180,000
$9.9 P/Share
|
|
Aug 31
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
78,495
-1.1%
|
$784,950
$10.6 P/Share
|
|
Aug 30
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,976
-0.84%
|
$670,736
$11.14 P/Share
|
|
Aug 29
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,854
-1.18%
|
$966,394
$11.15 P/Share
|
|
Aug 28
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
60,858
-1.6%
|
$669,438
$11.71 P/Share
|
|
Aug 25
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
84,656
-1.1%
|
$846,560
$10.93 P/Share
|
|
Aug 24
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
139,280
-3.46%
|
$1,949,920
$14.62 P/Share
|
|
Aug 23
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
121,103
-2.92%
|
$1,574,339
$13.05 P/Share
|
|
Aug 22
2023
|
Ew Healthcare Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
46,778
-1.12%
|
$654,892
$14.62 P/Share
|
|
Jul 11
2023
|
Karen L. Zaderej |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
-
|